Protection against varicella with two doses of combined measles-mumps-rubella-varicella vaccine or one dose of monovalent varicella vaccine: 10-year follow-up of a phase 3 multicentre, observer-blind, randomised, controlled trial

<p>The Cost-Effectiveness of Universal Varicella Vaccination in Italy: A Model-Based Assessment of Vaccination Strategies</p>

“…Secondly, there are limited data available comparing Varivax/ProQuad to Varilrix/ Priorix-Tetra; however, first, Varivax and ProQuad are generally consider to be immunologically equivalent to each other, as are Varilrix and Priorix-Tetra; second, two head-to-head studies 58,69 one in an outbreak setting in Germany, one in real-word use in Taiwanboth show similar patterns in differences in effectiveness after a single dose as the way that we (and others) 49,50,52,68 reflect take and waning in our models. Little is known about the performance of the effectiveness of the two-dose strategies involving Vaccine B and/or Vaccine D when used in long-interval settings, as all the recent clinical trial data 51,53 are based on administration of the doses only 3 months apart, rather than several years apart. Data is available on the real-world effectiveness of both Varivax 48 and ProQuad 70 on long-interval schedules, with results consistent with how they are modelled in this study.…”

“…Effectiveness (take and waning) for QQVa and MQVa were taken from a simple dynamic model 26 based on Kuter 2004; 47 for QQVb and MQVb, they were referenced from parameters reported in modeling papers based on Prymula 2014, [49][50][51][52] and supported by recently published evidence in the extension of the Prymula trial. 53,54 Importantly, this framework accounts for the significance of time since vaccination in modelling the force of infection and waning of vaccinederived protection, which is critical to capturing actual vaccine impact. Recent meta-analyses [55][56][57] examining various aspects of varicella vaccine effectiveness have not always accounted for this factor; those that do have found more differences between vaccines made by different manufacturers.…”

Vaccine confidence: the keys to restoring trust

“…Today, the mechanisms by which host and pathogen gene polymorphisms may influence immune responses to vaccines are better understood, but this complexity can be difficult to communicate (Supplement Text Box 1). 67,[103][104][105][106][107][108][109][110][111][112] Furthermore, the mitigation of severity and duration of the disease is an important benefit of routine vaccination. Therefore, although vaccines do not always produce a full immune response, they may nevertheless lessen disease symptoms, as seen with influenza, pertussis and rotavirus vaccines.…”

“…The pharmaceutical industry could do more to address people's concerns with information suited to different audiences, such as video summaries of scientific articles, 104 and plain language summaries of clinical trials.…”

Recomendación del CAVEI sobre la introducción de vacuna contra varicela al Programa Nacional de Inmunizaciones

“…Sus resultados mostraron que, a una mediana de seguimiento de 9,8 años, la eficacia contra varicela de todo tipo fue 95,4% para SRPV (94,0; 96,4 IC 95% ) y 67,2% para V (62,3; 71,5 IC 95% ); eficacia contra varicela moderada o grave fue 99,1% para SRPV (97,9 ; 99,6 IC 95% ) y 89,5% para SRP+V (86,1; 92,1 IC 95% ). Eventos adversos serios fueron reportados en 15% de los niños del grupo SRPV, 16% del grupo SRP+V y en 15% del grupo control 17 .…”